赵杰,郝家林,赵雪燕,张继胤,张洪亮国家心血管病中心北京协和医学院中国医学科学院阜外医院冠心病诊治中心,王彬成,孙中伟

• 1:国家心血管病中心北京协和医学院中国医学科学院阜外医院冠心病诊治中心
• 2:邢台市威县人民医院心血管内科

摘要(Abstract)：

目的评估冠状动脉慢性完全闭塞(CTO)病变患者经皮冠状动脉介入治疗(PCI)围术期应用比伐芦定的有效性和安全性。方法选取2018年5月24日至2019年3月12日在北京阜外医院住院并行CTO-PCI患者78例。根据术中使用抗凝药物情况将患者分为比伐芦定组(39例)和普通肝素组(39例)。观察比较两组术后主要不良心血管事件(MACE)和总出血及并发症事件的发生情况。结果比伐芦定组与普通肝素组围术期心肌损伤发生率(2.6%比5.1%,P=0.556)、围术期心肌梗死发生率(15.4%比10.3%,P=0.498)比较,差异均无统计学意义。两组患者在全因死亡、心脏死亡、计划外的血运重建、缺血事件上均未见不良事件,差异均无统计学意义(均P>0.05)。比伐芦定组与普通肝素组出血学术研究联合会分型(BARC)1型出血事件发生率(12.8%比10.3%,P=0.723)、BARC 2型出血事件发生率(2.6%比0,P>0.999)比较,差异均无统计学意义。两组患者均未发生BARC 3～5型严重出血事件。两组患者冠状动脉穿孔发生率(0比2.6%,P>0.999)比较,差异无统计学意义。结论与常规应用肝素抗凝治疗比较,比伐芦定在CTO-PCI中的应用是安全和有效的,在出血高风险患者中应用能否获益仍需较大样本的研究进一步证实。

关键词(KeyWords)： 比伐芦定;慢性完全闭塞病变;经皮冠状动脉介入治疗

Abstract:

Keywords:

基金项目(Foundation): 多中心评估比伐卢定对择期经皮冠状动脉介入治疗患者有效性及安全性和糖尿病亚组及血小板功能和基因检测亚组分析

作者(Author): 赵杰,郝家林,赵雪燕,张继胤,张洪亮国家心血管病中心北京协和医学院中国医学科学院阜外医院冠心病诊治中心,王彬成,孙中伟

参考文献(References)：

• [1]Zeymer U,Rao SV,Montalescot G.Anticoagulation in coronary intervention.Eur Heart J,2016,37(45):3376-3385.
• [2]Degrauwe S,Muller O,ZuffiA,et al.Percutaneous coronary intervention for chronic total occlusion:clinical perspectives in 2015.Rev Med Suisse,2015,11(476):1172-1179.
• [3]张弛，钱菊英．慢性完全闭塞性病变的介入治疗.中国临床医学，2009,16 (3):352-355.
• [4]Ndrepepa G,Berger PB,Mehilli J,et al.Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions:Appropriateness of including bleeding as a component of a quadruple end point.J Am Coll Cardiol,2008,51(7):690-697.
• [5]Thygesen K,Alpert JS,Jaff e AS,et al.Fourth universal definition of myocardial infarction (2018).J Am Coll Cardiol,2018,72(18):2231-2264.
• [6]Mehran R,Rao SV,Bhatt DL,et al.Standardized bleeding definitions for cardiovascular clinical trials:a consensus report from the bleeding academic research consortium.Circulation,2011,123(23):2736-2747.
• [7]Reed MD,Bell D.Clinical pharmacology of bivalirudin.Pharmacotherapy,2002,22(6 Pt 2):105S-111S.
• [8]Van De Car DA,Rao SV,Ohman EM.Bivalirudin:a review of the pharmacology and clinical application.Expert Rev Cardiovasc Ther,2010,8(12):1673-1681.
• [9]Barria Perez AE,Rao SV,Jolly SJ,et al.Meta-analysis of eff ects of bivalirudin versus heparin on myocardial ischemic and bleeding outcomes after percutaneous coronary intervention.Am J Cardiol,2016,117(8):1256-1266.
• [10]Rashid MK,Singh K,Bernick J,et al.Periprocedural bivalirudin versus unf ractionated heparin during percutaneous coronary intervention f ollowing f ibrinolysis f or ST-Segment elevation myocardial infarction.J Invasive Cardiol,2019,31(12):E387-E391.
• [11]Han Y,Guo J,Zheng Y,et al.Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction:the BRIGHT randomized clinical trial.JAMA,2015,313(13):1336-1346.
• [12]陈纪言，陈良龙，葛均波，等．中国冠状动脉慢性完全闭塞病变介入治疗推荐路径．中国介入心脏病学杂志，2018,26(3):121-128．
• [13]Kearney K,Hira RS,Riley RF,et al.Update on the management of chronic total occlusions in coronary artery disease.Curr Atheroscler Rep,2017,19(4):19．
• [14]Li C,Xu R,Shen Y,et al.Bivalirudin in percutaneous coronary intervention for chronic total occlusion:A single-center pilot study.Catheter Cardiovasc Interv,2018,91(4):679-685．
• [15]Li CG,Shen Y,Xu RD,et al.Exploration of bivalirudin use during percutaneous coronary intervention for high bleeding risk patients with chronic total occlusion.Int Heart J,2018,59(2):293-299．
• [16]Wang Y,Zhao HW,Wang CF,et al.Efficacy and safety of bivalirudin during percutaneous coronary intervention in highbleeding-risk elderly patients with chronic total occlusion:Aprospective randomized controlled trial.Catheter Cardiovasc Interv,2019,93(S1):825-831.
• [17]孔令东，王耿，韩雅玲，等.比伐芦定在冠状动脉慢性完全闭塞病变介入治疗中应用的疗效.中华心血管病杂志，2018,46(7):543-548.